STORY: Taiwan-funded medical firm vows to further tap into Chinese mainland market
SHOOTING TIME: File & June 12, 2024
DATELINE: June 14, 2024
LENGTH: 0:01:23
LOCATION: XIAMEN, China
CATEGORY: ECONOMY

SHOTLIST:
1. various of Lihpao Biotechnology Co., Ltd.
2. SOUNDBITE (Chinese): LI MINGHUI, Assistant to the president of Lihpao Biotechnology Co., Ltd.

STORYLINE:

Lihpao Biotechnology Co., Ltd., a Taiwan-invested gene sequencing firm, entered the Chinese mainland market in 2016.

Based in China's eastern coastal city of Xiamen in Fujian Province, the company has grown rapidly due to the favorable business environment and supportive policies.

It has vowed to continue its pace of investing in the health sector in the coming years.

SOUNDBITE (Chinese): LI MINGHUI, Assistant to the president of Lihpao Biotechnology Co., Ltd.
"In the past three years, the company's business in Xiamen has grown exponentially, strengthening our confidence and determination to deeply cultivate the Chinese mainland market. The company will add about 5 million U.S. dollars of investment in introducing advanced equipment to better meet the needs of the mainland market.

The Chinese mainland has launched a series of opening-up policies, established platforms and mechanisms, and implemented practical projects. Moreover, the government has introduced a series of policies and measures to support the development of Taiwan-funded enterprises, creating a favorable business environment for our development.

Genetic testing and precision medicine are our specialties, and we have accumulated rich experience. The mainland market is vast and the demand is huge. We are full of confidence in the growth of the mainland market. Medical technology in the Chinese mainland is developing rapidly. We are very keen to join hands with the Chinese mainland to explore the relevant fields of precision medicine, bringing tangible benefits to people across the Taiwan Strait."

Xinhua News Agency correspondents reporting from Xiamen, China.
(XHTV)